MetaVia Inc. announced positive interim results from Part 3B of its Phase 1 clinical trial for DA-1726, a novel oxyntomodulin analog targeting GLP-1 and glucagon receptors. The data showed a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted reduction in body weight after 16 weeks of treatment. Participants also demonstrated improved glycemic control with HbA1c dropping from 5.79% to 5.33%. The company plans to initiate a Phase 2 study for metabolic dysfunction- and alcohol-associated liver disease (MetALD/ALD) in the second half of 2027. MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases.
